Expert panel urges limited use of J&J heart drug
Key points
- A panel of heart experts has recommended limited use of Johnson & Johnson's heart drug Natrecor (nesiritide) and backed the company's plan to conduct additional clinical trials, J&J said in a report issued late on Wednesday.
- J&J had requested the panel to meet to evaluate all data on the heart failure drug after reports surfaced that it increased the rate of kidney failure and death.
- Eugene Braunwald of Harvard Medical School, said the use of the drug should be "strictly limited" to severely ill congestive heart failure patients who are hospitalized.
- The panel said the drug should not be used for patients who are not in the hospital, nor should it be used to improve kidney function.
A panel of heart experts has recommended limited use of Johnson & Johnson's heart drug Natrecor (nesiritide) and backed the company's plan to conduct additional clinical trials, J&J said in a report issued late on Wednesday.
J&J had requested the panel to meet to evaluate all data on the heart failure drug after reports surfaced that it increased the rate of kidney failure and death.
The panel, which was led by Dr. Eugene Braunwald of Harvard Medical School, said the use of the drug should be "strictly limited" to severely ill congestive heart failure patients who are hospitalized.
The panel said the drug should not be used for patients who are not in the hospital, nor should it be used to improve kidney function.
The panel also urged the company to mount an educational program for physicians to inform them of the drug's appropriate uses.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Addiction →
NewsBayer forgot to tell risks of heart surgery drug
According to the German drug giant Bayer AG, the reason the company failed to inform U.S. regulators about a study on the risks of the heart-surgery drug Trasylol was a mistake. Bayer apparently knew the controversial…
4 October 2006
NewsExperts say Vioxx poses risks long after patients stop taking it
According to a leading American cardiologist patients who have taken the drug Vioxx are still at high risk of heart attacks or strokes even after they stop taking the medication. Dr. Steven Nissen has disputed Merck &…
17 May 2006
NewsPanel backs new warnings on ADHD drugs
U.S. advisers on Wednesday called for new information about psychiatric and heart risks on the labels of attention deficit drugs but stopped short of recommending the strongest possible warning, saying they did not want…
24 March 2006